Ikaros deficiency in host hematopoietic cells separates GVL from GVHD after experimental allogeneic hematopoietic cell transplantation

References

• Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, Martin PJ, Sandmaier BM, Marr KA, Appelbaum FR, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 2010; 363:2091-101; PMID:21105791; http://dx.doi.org/10.1056/NEJMoa1004383
   PubMed Web of Science ®Google Scholar
• Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F, et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol 2013; 31:1530-8; PMID:23478054; http://dx.doi.org/10.1200/JCO.2012.45.0247
   PubMed Web of Science ®Google Scholar
• Blazar BR, Murphy WJ, Abedi M. Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012; 12:443-58; PMID:22576252; http://dx.doi.org/10.1038/nri3212
   PubMed Web of Science ®Google Scholar
• Khaled SK, Thomas SH, Forman SJ. Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults. Curr Opin Oncol 2012; 24:182-90; PMID:22234252; http://dx.doi.org/10.1097/CCO.0b013e32834f5c41
   PubMed Web of Science ®Google Scholar
• Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL. A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med 2005; 11:1244-9; PMID:16227991; http://dx.doi.org/10.1038/nm1309
   PubMed Web of Science ®Google Scholar
• Toubai T, Sun Y, Luker G, Liu J, Luker KE, Tawara I, Evers R, Liu C, Mathewson N, Malter C, et al. Host-derived CD8+ dendritic cells are required for induction of optimal graft-versus-tumor responses after experimental allogeneic bone marrow transplantation. Blood 2013; 121:4231-41; PMID:23520337; http://dx.doi.org/10.1182/blood-2012-05-432872
   PubMed Web of Science ®Google Scholar
• Toubai T, Sun Y, Tawara I, Friedman A, Liu C, Evers R, Nieves E, Malter C, Chockley P, Maillard I, et al. Ikaros-Notch axis in host hematopoietic cells regulates experimental graft-versus-host disease. Blood 2011; 118:192-204; PMID:21471527; http://dx.doi.org/10.1182/blood-2010-12-324616
   PubMedGoogle Scholar
• Georgopoulos K, Moore DD, Derfler B. Ikaros, an early lymphoid-specific transcription factor and a putative mediator for T cell commitment. Science 1992; 258:808-12; PMID:1439790; http://dx.doi.org/10.1126/science.1439790
   PubMed Web of Science ®Google Scholar
• Georgopoulos K, Bigby M, Wang JH, Molnar A, Wu P, Winandy S, Sharpe A. The Ikaros gene is required for the development of all lymphoid lineages. Cell 1994; 79:143-56; PMID:7923373; http://dx.doi.org/10.1016/0092-8674(94)90407-3
   PubMed Web of Science ®Google Scholar
• Winandy S, Wu P, Georgopoulos K. A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma. Cell 1995; 83:289-99; PMID:7585946; http://dx.doi.org/10.1016/0092-8674(95)90170-1
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Su X, Zhang J, Radtke I, Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360:470-80; PMID:19129520; http://dx.doi.org/10.1056/NEJMoa0808253
   PubMed Web of Science ®Google Scholar
• Martinelli G, Iacobucci I, Storlazzi CT, Vignetti M, Paoloni F, Cilloni D, Soverini S, Vitale A, Chiaretti S, Cimino G, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol 2009; 27:5202-7; PMID:19770381; http://dx.doi.org/10.1200/JCO.2008.21.6408
   PubMed Web of Science ®Google Scholar
• Vegh Z, Goyarts EC, Rozengarten K, Mazumder A, Ghebrehiwet B. Maturation-dependent expression of C1q-binding proteins on the cell surface of human monocyte-derived dendritic cells. Int Immunopharmacol 2003; 3:345-57; PMID:12639812; http://dx.doi.org/10.1016/S1567-5769(02)00234-5
   PubMedGoogle Scholar
• Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005; 123:321-34; PMID:16239148; http://dx.doi.org/10.1016/j.cell.2005.08.032
   PubMed Web of Science ®Google Scholar
• Gao B, Adhikari R, Howarth M, Nakamura K, Gold MC, Hill AB, Knee R, Michalak M, Elliott T. Assembly and antigen-presenting function of MHC class I molecules in cells lacking the ER chaperone calreticulin. Immunity 2002; 16:99-109; PMID:11825569; http://dx.doi.org/10.1016/S1074-7613(01)00260-6
   PubMed Web of Science ®Google Scholar
• Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, Shlomchik MJ, Emerson SG. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285:412-5; PMID:10411505; http://dx.doi.org/10.1126/science.285.5426.412
   PubMed Web of Science ®Google Scholar
• Raghavan M, Wijeyesakere SJ, Peters LR, Del Cid N. Calreticulin in the immune system: ins and outs. Trends Immunol 2013; 34:13-21; PMID:22959412; http://dx.doi.org/10.1016/j.it.2012.08.002
   PubMed Web of Science ®Google Scholar
• Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR, Ferrara JL. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med 2002; 8:575-81; PMID:12042807; http://dx.doi.org/10.1038/nm0602-575
   PubMed Web of Science ®Google Scholar
• Matte CC, Liu J, Cormier J, Anderson BE, Athanasiadis I, Jain D, McNiff J, Shlomchik WD. Donor APCs are required for maximal GVHD but not for GVL. Nat Med 2004; 10:987-92; PMID:15286785; http://dx.doi.org/10.1038/nm1089
   PubMed Web of Science ®Google Scholar
• Radford KJ, Tullett KM, Lahoud MH. Dendritic cells and cancer immunotherapy. Curr Opin Immunol 2014; 27:26-32; PMID:24513968; http://dx.doi.org/10.1016/j.coi.2014.01.005
   PubMed Web of Science ®Google Scholar
• Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012; 12:265-77; PMID:22437871; http://dx.doi.org/10.1038/nrc3258
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Eom HS, Sachs J, Buchli J, Cotter P, Hsu R, Zhao G, Sykes M. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood 2006; 108:2106-13; PMID:16757687; http://dx.doi.org/10.1182/blood-2006-03-007427
   PubMed Web of Science ®Google Scholar
• Bozzacco L, Trumpfheller C, Siegal FP, Mehandru S, Markowitz M, Carrington M, Nussenzweig MC, Piperno AG, Steinman RM. DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci U S A 2007; 104:1289-94; PMID:17229838; http://dx.doi.org/10.1073/pnas.0610383104
   PubMed Web of Science ®Google Scholar
• Moron G, Rueda P, Casal I, Leclerc C. CD8alpha- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules. J Exp Med 2002; 195:1233-45; PMID:12021304; http://dx.doi.org/10.1084/jem.20011930
   PubMed Web of Science ®Google Scholar
• Yamazaki S, Dudziak D, Heidkamp GF, Fiorese C, Bonito AJ, Inaba K, Nussenzweig MC, Steinman RM. CD8+ CD205+ splenic dendritic cells are specialized to induce Foxp3+ regulatory T cells. J Immunol 2008; 181:6923-33; PMID:18981112; http://dx.doi.org/10.4049/jimmunol.181.10.6923
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly J, et al. Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med 2014; 6:232ra51; PMID:24739759; http://dx.doi.org/10.1126/scitranslmed.3008068
   PubMed Web of Science ®Google Scholar
• Zeng G, Aldridge ME, Tian X, Seiler D, Zhang X, Jin Y, Rao J, Li W, Chen D, Langford MP, et al. Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system. J Immunol 2006; 177:3582-9; PMID:16951317; http://dx.doi.org/10.4049/jimmunol.177.6.3582
   PubMed Web of Science ®Google Scholar
• Basu S, Srivastava PK. Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J Exp Med 1999; 189:797-802; PMID:10049943; http://dx.doi.org/10.1084/jem.189.5.797
   PubMed Web of Science ®Google Scholar
• Nair S, Wearsch PA, Mitchell DA, Wassenberg JJ, Gilboa E, Nicchitta CV. Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. J Immunol 1999; 162:6426-32; PMID:10352256
   PubMed Web of Science ®Google Scholar
• Bak SP, Amiel E, Walters JJ, Berwin B. Calreticulin requires an ancillary adjuvant for the induction of efficient cytotoxic T cell responses. Mol Immunol 2008; 45:1414-23; PMID:17936359; http://dx.doi.org/10.1016/j.molimm.2007.08.020
   PubMed Web of Science ®Google Scholar
• Del Cid N, Jeffery E, Rizvi SM, Stamper E, Peters LR, Brown WC, Provoda C, Raghavan M. Modes of calreticulin recruitment to the major histocompatibility complex class I assembly pathway. J Biol Chem 2010; 285:4520-35; PMID:19959473; http://dx.doi.org/10.1074/jbc.M110.166330
   PubMed Web of Science ®Google Scholar
• Howe C, Garstka M, Al-Balushi M, Ghanem E, Antoniou AN, Fritzsche S, Jankevicius G, Kontouli N, Schneeweiss C, Williams A, et al. Calreticulin-dependent recycling in the early secretory pathway mediates optimal peptide loading of MHC class I molecules. EMBO J 2009; 28:3730-44; PMID:19851281; http://dx.doi.org/10.1038/emboj.2009.296
   PubMedGoogle Scholar
• van der Veer A, Zaliova M, Mottadelli F, De Lorenzo P, Te Kronnie G, Harrison CJ, Cavé H, Trka J, Saha V, Schrappe M, et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood 2014; 123:1691-8; PMID:24366361; http://dx.doi.org/10.1182/blood-2013-06-509794
   PubMed Web of Science ®Google Scholar
• Mavrakis KJ, Van Der Meulen J, Wolfe AL, Liu X, Mets E, Taghon T, Khan AA, Setty M, Rondou P, Vandenberghe P, et al. A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet 2011; 43:673-8; PMID:21642990; http://dx.doi.org/10.1038/ng.858
   PubMed Web of Science ®Google Scholar
• Nakayama H, Ishimaru F, Avitahl N, Sezaki N, Fujii N, Nakase K, Ninomiya Y, Harashima A, Minowada J, Tsuchiyama J, et al. Decreases in Ikaros activity correlate with blast crisis in patients with chronic myelogenous leukemia. Cancer Res 1999; 59:3931-4; PMID:10463586
   PubMed Web of Science ®Google Scholar
• Kuiper RP, Waanders E, van der Velden VH, van Reijmersdal SV, Venkatachalam R, Scheijen B, Sonneveld E, van Dongen JJ, Veerman AJ, van Leeuwen FN, et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia 2010; 24:1258-64; PMID:20445578; http://dx.doi.org/10.1038/leu.2010.87
   PubMed Web of Science ®Google Scholar
• Waanders E, van der Velden VH, van der Schoot CE, van Leeuwen FN, van Reijmersdal SV, de Haas V, Veerman AJ, van Kessel AG, Hoogerbrugge PM, Kuiper RP, et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia 2011; 25:254-8; PMID:21102428; http://dx.doi.org/10.1038/leu.2010.275
   PubMed Web of Science ®Google Scholar
• Wang JH, Nichogiannopoulou A, Wu L, Sun L, Sharpe AH, Bigby M, Georgopoulos K. Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity 1996; 5:537-49; PMID:8986714; http://dx.doi.org/10.1016/S1074-7613(00)80269-1
   PubMed Web of Science ®Google Scholar
• Cooke KR, Kobzik L, Martin TR, Brewer J, Delmonte J Jr, Crawford JM, Ferrara JL. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood 1996; 88:3230-9; PMID:8963063
   PubMed Web of Science ®Google Scholar
• Chen W, Qin H, Chesebro B, Cheever MA. Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol 1996; 70:7773-82; PMID:8892898
   PubMedGoogle Scholar
• Facchinetti A, Dalla Santa S, Mezzalira S, Rosato A, Biasi G. A large number of T lymphocytes recognize Moloney-murine leukemia virus-induced antigens, but a few mediate long-lasting tumor immunosurveillance. J Immunol 2005; 174:5398-406; PMID:15843538; http://dx.doi.org/10.4049/jimmunol.174.9.5398
   PubMed Web of Science ®Google Scholar
• van Hall T, van Bergen J, van Veelen PA, Kraakman M, Heukamp LC, Koning F, Melief CJ, Ossendorp F, Offringa R. Identification of a novel tumor-specific CTL epitope presented by RMA, EL-4, and MBL-2 lymphomas reveals their common origin. J Immunol 2000; 165:869-77; PMID:10878361; http://dx.doi.org/10.4049/jimmunol.165.2.869
   PubMedGoogle Scholar
• Teshima T, Hill GR, Pan L, Brinson YS, van den Brink MR, Cooke KR, Ferrara JL. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest 1999; 104:317-25; PMID:10430613; http://dx.doi.org/10.1172/JCI7111
   PubMed Web of Science ®Google Scholar
• Cooke KR, Gerbitz A, Crawford JM, Teshima T, Hill GR, Tesolin A, Rossignol DP, Ferrara JL. LPS antagonism reduces graft-versus-host disease and preserves graft-versus-leukemia activity after experimental bone marrow transplantation. J Clin Invest 2001; 107:1581-9; PMID:11413166; http://dx.doi.org/10.1172/JCI12156
   PubMed Web of Science ®Google Scholar
• Duran-Struuck R, Tawara I, Lowler K, Clouthier SG, Weisiger E, Rogers C, Luker G, Kumanogoh A, Liu C, Ferrara JL, et al. A novel role for the semaphorin Sema4D in the induction of allo-responses. Biol Blood Marrow Transplant 2007; 13:1294-303; PMID:17950916
   PubMedGoogle Scholar